---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-352186"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2026-08-14T20:05:16+00:00"
generated_at: "2026-08-14T20:10:18.530447+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma appoints Robert Gunning as principal accounting officer

## Summary
- Robert W. Gunning, 55, appointed principal accounting officer effective Aug 10, 2026, succeeding Louise Kooij (departs Aug 31, 2026).
- Gunning joined as VP Controller; base salary $375,000/year, target bonus 30% of base, prorated for first year.
- Equity grant: RSU covering 3,200 ordinary shares and option for 14,000 shares under 2024 Inducement Plan.
- Prior roles: Interim Controller at Altimmune (Apr-Jul 2026), VP Finance/Controller at Y-mAbs (2022-2026), VP Controller at Excision Biotherapeutics (2021-2022).

## SEC filing metadata
- accession: 0001193125-26-352186
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2026-08-14T20:05:16+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/0001193125-26-352186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/nams-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-352186
- JSON: https://secwatch.observer/filing/0001193125-26-352186.json
- Plain text: https://secwatch.observer/filing/0001193125-26-352186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.